poisar

Stock

Quince Therapeutics, Inc. QNCX

$32.23+1.51%

Overview

QNCX market data

Price History

QNCX price chart · 1M
O
31.32
H
32.23
L
31.22
C
32.23
Vol
670.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$31.32
Previous Close
$31.75
Day High
$32.23
Day Low
$31.22
52 Week High
$35.41
52 Week Low
$15.79
7 Day Return
-2.69%
30 Day Return
+71.44%
90 Day Return
+39.52%
1 Year Return
+32.09%
Daily Notional Volume
$21.6K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$335.27
Diluted earnings per share over the trailing twelve months.
Beta
1.31
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$15.10 – $910.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $33.6M · P/B 2.73.

Company News

9 captured
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price TargetBenzinga · Aug 18, 2026, 10:59 AM
8-K filing — Quince Therapeutics, Inc. (QNCX)SEC EDGAR · Aug 17, 2026, 10:01 AM
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) EstimateBenzinga · Aug 14, 2026, 12:19 PM
Quince Therapeutics Says Brigette Roberts Conditionally Appointed As CEO; John Militello Conditionally Appointed As CFOBenzinga · Jul 31, 2026, 8:55 PM
Quince Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $82 price target.Benzinga · Jul 29, 2026, 5:52 PM
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82Benzinga · Jul 29, 2026, 4:23 PM
8-K/A filing — Quince Therapeutics, Inc. (QNCX)SEC EDGAR · Jun 26, 2026, 8:31 PM
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4Benzinga · Jun 24, 2026, 6:50 PM
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4Benzinga · Jun 23, 2026, 4:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock